UK markets closed

Convatec Group Plc (CTEC.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
251.00+2.60 (+1.05%)
At close: 04:35PM GMT

Convatec Group Plc

3 Forbury Place
23 Forbury Road
Reading RG1 3JH
United Kingdom
44 11 8952 8100
https://www.convatecgroup.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full-time employees10,000

Key executives

NameTitlePayExercisedYear born
Mr. Karim BitarCEO & Director2.45MN/A1965
Mr. Jonathan Peter MasonGroup CFO & Director1.06MN/A1964
Mr. John HallerExecutive VP and Chief Quality & Operations OfficerN/AN/AN/A
Dr. Divakar Ramakrishnan Ph.D.Executive VP, Chief Technology Officer and Head of Research & DevelopmentN/AN/AN/A
Ms. Kate PostansVice President of Investor Relations & Corporate CommunicationsN/AN/AN/A
Ms. Evelyn Douglas J.D.Executive VP, Chief of Corporate Strategy & Business Development and General CounselN/AN/AN/A
Ms. Natalia KozminaExecutive VP, Chief Human Resources Officer & ESG StewardshipN/AN/AN/A
Ms. Kjersti Grimsrud Biotechnology, M.Sc.President & COO of Infusion CareN/AN/A1961
Mr. Supratim BosePresident & COO of Global Emerging MarketsN/AN/A1952
Mr. David ShepherdPresident & COO of Global Advanced Wound CareN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

ConvaTec Group PLC engages in the development, manufacture, and marketing of medical products and technologies worldwide. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence and critical care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as Parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Corporate governance

Convatec Group Plc’s ISS governance QualityScore as of 1 February 2024 is 2. The pillar scores are Audit: 3; Board: 3; Shareholder rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.